VPC
DRUG

Vestal Point Capital’s Bright Minds Biosciences DRUG Stock Holding History

Vestal Point Capital’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.3M Buy
545,000
+52,681
+11% +$4.14M 0.89% 31
2026
Q1 		$35.9M Buy
+492,319
New +$39.6M 1% 36

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vestal Point Capital's DRUG Position: Q2 2026 in Review

Vestal Point Capital increased its Bright Minds Biosciences (DRUG) stake by 11% in Q2 2026, buying an estimated $4.14M and bringing the position to 545,000 shares worth $38.3M. The position accounts for 0.89% of the portfolio, ranked #31.

Vestal Point Capital first reported a position in DRUG in Q1 2026 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Vestal Point Capital held 545,000 shares of Bright Minds Biosciences worth $38.3M as of Q2 2026.
  • Vestal Point Capital bought 52,681 Bright Minds Biosciences shares in Q2 2026, an estimated $4.14M.
  • Bright Minds Biosciences made up 0.89% of Vestal Point Capital's portfolio in Q2 2026, its #31 holding.
  • Vestal Point Capital first reported a position in Bright Minds Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.